Selank

Mechanism of Action

Selank is a synthetic heptapeptide derived from tuftsin, a naturally occurring immunomodulatory peptide. It is designed to resist enzymatic degradation, giving it a longer half-life than its parent compound.

Research suggests Selank modulates the GABAergic and serotonergic neurotransmitter systems, potentially enhancing inhibitory neurotransmission. It has been reported to affect expression of brain-derived neurotrophic factor (BDNF) and interleukin-6 (IL-6) in brain tissue.

Additionally, Selank may influence the activity of enkephalin-degrading enzymes, potentially increasing endogenous enkephalin levels and contributing to its reported anxiolytic effects without the sedation associated with traditional benzodiazepines.

Reported Effects

Commonly Reported

• Reduced anxiety symptoms in Phase II trials (comparable to diazepam in some measures)
• Improved cognitive performance under stress conditions
• Enhanced memory consolidation in animal models
• Stabilization of mood in healthy volunteers

Less Common Reports

• Immunomodulatory effects (altered cytokine profiles)
• Potential antidepressant-like activity
• Neuroprotective effects in ischemia models
• Modulation of pain perception

Clinical data primarily originates from Institute of Molecular Genetics (Moscow) studies.

Side Effects & Safety Profile

Low Concern

• Mild nasal irritation (intranasal administration)
• Occasional headache
• Generally well-tolerated in published trials

Moderate Concern

• Limited data outside of Russian-language literature
• Long-term safety data is sparse
• Potential for tolerance with extended use (undetermined)

Serious

• No serious adverse events reported in available clinical data
• Independent replication of Russian studies is limited
• Purity and dosing consistency are variable in non-pharmaceutical sources

Clinical Evidence

Most clinical evidence for Selank comes from Russian research institutions:

• Phase II trials conducted at the Institute of Molecular Genetics (Russian Academy of Sciences) demonstrated anxiolytic effects comparable to low-dose benzodiazepines without sedation or cognitive impairment
• Studies in patients with anxiety-phobic disorders showed symptom improvement over 14–28 day treatment periods
• Cognitive enhancement observed in healthy volunteers under psychogenic stress conditions
• Neuroprotective effects demonstrated in rodent cerebral ischemia models

International peer-reviewed publications remain limited. Independent replication of findings is needed.

Discovery Timeline

• 1982 — Tuftsin identified as an immunomodulatory tetrapeptide
• 1990s — Selank (TP-7) synthesized at Institute of Molecular Genetics, Moscow
• 2003–2009 — Phase II clinical trials conducted in Russia for anxiety disorders
• 2009 — Approved for medical use in Russia (anxiolytic)
• 2010s — Growing interest in Western nootropic community
• 2020s — Research interest expanding; international clinical data still limited

Clinical Evidence

The clinical evidence for Selank derives primarily from research conducted at the Institute of Molecular Genetics (IMG) of the Russian Academy of Sciences in Moscow, where the compound was synthesised and developed across the 1990s and early 2000s. Phase II trials were completed in Russia between approximately 2003 and 2009, focusing on patients with generalised anxiety disorder and mixed anxiety-depressive disorder. These studies demonstrated statistically significant reductions in Hamilton Anxiety Rating Scale (HAM-A) and Spielberger State-Trait Anxiety Inventory (STAI) scores over 14–28 day treatment courses. A notable finding was that Selank's anxiolytic efficacy was rated broadly comparable to low-dose diazepam (2.5–5 mg daily equivalent) without the sedation, psychomotor impairment, or dependency potential associated with benzodiazepines. Cognitive performance under induced psychogenic stress was preserved or improved, rather than degraded as is typically observed with benzodiazepine treatment.

Mechanistic studies from the same group identified upregulation of BDNF (brain-derived neurotrophic factor) mRNA in the hippocampus and frontal cortex following Selank administration in rodents, a finding with potential implications for its cognitive-enhancing and antidepressant-adjacent effects. Changes in IL-6 and related cytokines suggested an immunomodulatory component that may contribute to the stress-adaptive phenotype.

The principal limitation of this evidence base is structural: the majority of primary literature is published in Russian-language journals with limited international indexing, peer review practices that differ from those in Western clinical trial frameworks, and no independent replication by research groups outside Russia. Western-language reviews and secondary analyses exist but rely on the same underlying dataset. The compound was approved for medical use in Russia in 2009 as an anxiolytic, which reflects regulatory confidence within that system, but this approval does not satisfy the evidentiary standards of the FDA, EMA, or equivalent bodies. Evidence grade: B. Phase II data available; independent replication and Phase III trials remain absent.

Dosing & Administration

Selank is administered intranasally using a solution reconstituted from lyophilised powder or supplied pre-mixed at concentrations typically ranging from 0.15% to 0.5% (1.5–5 mg/mL). The standard research dosing range across published protocols is 300–900 mcg per administration, delivered as drops or a measured spray into one or both nostrils. At a 0.15% concentration, this corresponds to 20–60 µL per dose.

Dosing frequency in clinical trials was typically two to three times daily, with the lower end (2×/day) sufficient for anxiolytic effects in many subjects and three-times-daily dosing used in protocols targeting both mood and cognitive enhancement. Total daily doses in trials ranged from 600 mcg to 2,700 mcg, with the 900 mcg twice-daily schedule (1,800 mcg/day) representing a commonly reported middle ground.

Vial preparation: Lyophilised Selank is reconstituted with bacteriostatic water or sterile saline. Solutions should be stored refrigerated at 2–8°C and used within 30 days of reconstitution. Freezing the reconstituted solution is not recommended as it may affect peptide stability.

Cycling: Tolerance data in humans is limited, but community practice commonly employs cycles of 2–4 weeks on followed by 1–2 weeks off to prevent any potential receptor adaptation. The short half-life of Selank in solution and its rapid intranasal action make it suitable for as-needed use as well as scheduled daily dosing, with some users reserving it for high-stress periods rather than continuous administration.

Community Research Notes

The following accounts are compiled from self-reported research logs and community forums focused on cognitive enhancement and peptide research. They do not constitute medical advice.

I've tried several anxiolytics over the years including a period on lorazepam, which I found effective but cognitively dulling in a way I hated. Selank at 600 mcg twice daily is genuinely different. The anxiety is quieter — more like the baseline calm I imagine non-anxious people have — but I feel sharp. I did a writing session last week that was some of the best focused work I've done in months. Three weeks in, intranasal, no nasal irritation beyond the first day.

— Male, 29, generalised anxiety, cognitive performance focus

Social situations used to cost me a lot of mental energy — I'd be running social autopsy scripts in my head for hours after any conversation. After ten days of Selank at 500 mcg three times daily, the post-event rumination dropped dramatically. Interactions feel more natural and I'm not exhausted afterward. I've tried ashwagandha and L-theanine previously, neither came close to this effect size. The intranasal delivery was strange at first but I got used to it within two days.

— Female, 33, social anxiety, professional environment

I'm a researcher and I started Selank primarily for cognitive clarity during high-workload periods rather than anxiety per se. What I found was that my general stress reactivity dropped — small setbacks didn't spiral the same way. Focus during complex analysis felt cleaner. I've been cycling it two weeks on, one week off at 300 mcg three times daily. I notice the off-weeks now; there's a mild return of background stress that makes the contrast clear. No side effects to speak of beyond occasional mild nasal dryness.

— Non-binary, 38, academic researcher, cognitive enhancement primary goal

I was very sceptical given how much of the research is Russian-language and not independently replicated. Decided to try a single two-week cycle before forming an opinion. By day five I noticed I was less reactive to my usual stress triggers. By day ten I was sleeping better and the anxious 3 AM wake-ups that have plagued me for years had mostly stopped. I paired it with Semax in the second week and the combination felt notably more nootropic than either alone. I'll be running a second cycle with better tracking before concluding anything.

— Male, 45, self-described sceptic, sleep and anxiety focus

Frequently Asked Questions

Is Selank addictive?

Based on available clinical and preclinical evidence, Selank does not appear to carry a dependency or addiction liability. Its mechanism does not involve direct agonism of GABA-A benzodiazepine binding sites, mu-opioid receptors, or dopamine reward circuits in the way that classical anxiolytics and sedatives do. Animal studies found no evidence of conditioned place preference or escalating self-administration — behavioural markers of addiction potential. In Phase II trials, discontinuation did not produce withdrawal symptoms or rebound anxiety beyond a gradual return to pre-treatment baseline. Community reports occasionally describe a subjective desire to continue use — which is not the same as physiological dependence — primarily because the compound is effective and pleasant to use. Caution is nonetheless warranted given the limited long-term data: the absence of evidence for addiction potential from short Phase II studies is not the same as confirmed safety over multi-year continuous use.

How does Selank compare to benzodiazepines?

The key distinctions are sedation, cognitive effects, and dependency risk. Benzodiazepines act as positive allosteric modulators at GABA-A receptors, producing broad inhibitory activity across the CNS that is anxiolytic but also sedating, amnestic, and associated with tolerance and physical dependence. Selank appears to modulate GABAergic and serotonergic tone more selectively, producing anxiolysis without the sedation or psychomotor impairment that characterises benzodiazepine use. In clinical comparisons, subjects on Selank maintained or improved cognitive performance under stress tests while diazepam-treated subjects showed the expected impairment. The tradeoff is potency: benzodiazepines can provide rapid and powerful sedation and are essential in acute crisis situations (seizures, severe panic) where Selank would be inadequate. For chronic low-to-moderate anxiety management, Selank's profile — effective anxiolysis, preserved cognition, no dependency — is arguably superior if the evidence base were more robust.

How long until effects are felt?

Intranasal administration produces relatively rapid onset: many users report subjective changes within 20–40 minutes of a dose, reflecting the efficient nasal mucosal absorption route. The full stabilising effect on chronic anxiety, however, is typically reported to accumulate over 5–14 days of consistent dosing, consistent with the timescales observed in Phase II trials where significant HAM-A score improvements were evident by the end of the first week but continued developing through the full 14–28 day course. This dual timeline — acute dose effect plus a cumulative adaptive effect — distinguishes Selank from both benzodiazepines (primarily acute) and SSRIs (typically 4–6 weeks to efficacy), and represents one of the more practical aspects of its clinical profile.

Can Selank be combined with Semax?

Semax is a synthetic ACTH(4-7) analogue with distinct nootropic and neuroprotective properties, also primarily researched in Russia. The two compounds have complementary rather than overlapping mechanisms: Selank is primarily anxiolytic and mood-stabilising, while Semax is more directly pro-cognitive, with established effects on BDNF upregulation, dopaminergic tone, and concentration. They are frequently used together in the Russian nootropic research tradition and in Western peptide research communities. Community reports consistently describe the combination as synergistic for both anxiety management and cognitive performance, with neither compound appearing to attenuate the other. Both are intranasal, which simplifies co-administration. There is no formal clinical trial data on the combination; the interaction evidence is entirely observational. Typical paired protocols use each at the lower end of their dosing ranges when combined, as the subjective effects of both can be more pronounced together.

What is the best administration protocol?

Based on available trial protocols and community practice, a pragmatic starting approach is 300 mcg intranasally twice daily (morning and early afternoon) for the first five days to assess tolerability, then escalating to 500–600 mcg twice daily for a two-week course. Three-times-daily dosing (morning, midday, early evening) is used for enhanced nootropic effect or more persistent anxiety symptoms. The preparation should be administered with the head slightly tilted forward rather than back, to encourage mucosal absorption rather than pharyngeal drainage. One dose per nostril (alternating or both simultaneously) at each administration event. Refrigerate the solution and discard any reconstituted vial beyond 30 days. Allow 1–2 weeks off between cycles. Morning administration is preferred for the first dose to assess whether any individual experiences stimulant-adjacent effects from the nootropic component that could interfere with sleep.

Compounds That Pair Well

Semax

Semax is the most commonly recommended companion to Selank within nootropic research stacks, and the pairing has enough community consensus behind it to warrant serious consideration. Where Selank primarily reduces anxiety and stabilises mood, Semax acts more directly on cognitive performance — enhancing attention, working memory, and mental stamina through BDNF upregulation, increased dopaminergic neurotransmission in prefrontal circuits, and ACTH-related effects on alertness. The net effect of the combination, as frequently reported, is anxiolytic calm paired with cognitive sharpness — two properties that independently tend to trade off against each other in conventional pharmacology (sedating anxiolytics blunt cognition; stimulating nootropics worsen anxiety). Both compounds are intranasal, making simultaneous administration practical. Standard research pairing uses Selank 300–600 mcg and Semax 300–600 mcg per administration session, two to three times daily. Cycle them together over two to three week periods.

BPC-157

BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide derived from gastric juice, studied for systemic healing, gut protection, and neurological effects. Its inclusion alongside Selank is justified on several grounds: BPC-157 has shown anxiolytic-adjacent properties in animal models via dopamine and serotonin system modulation; it appears to support gut-brain axis integrity (relevant given the bidirectional relationship between gut health and anxiety); and it has a broad safety and tolerability profile that complements Selank's narrow focus. In community use, BPC-157 is often added as a general wellness foundation to nootropic stacks rather than for a specific synergistic mechanism with Selank. Subcutaneous or oral BPC-157 (200–500 mcg daily) is commonly used alongside intranasal Selank without reported adverse interactions.

NA-Selank Amidate

NA-Selank Amidate (N-acetyl Selank Amidate) is a modified variant of Selank with N-terminal acetylation and C-terminal amidation. These modifications increase resistance to enzymatic degradation, extending half-life and potentially increasing potency relative to standard Selank. Community reports suggest NA-Selank Amidate produces comparable or stronger effects at lower doses (100–300 mcg per administration versus 300–900 mcg for standard Selank), which can reduce the practical cost per dose. The two forms are not typically combined — NA-Selank Amidate is best understood as a more potent alternative rather than a complement. Researchers switching from standard Selank should start at the lower end of the NA-Selank Amidate dosing range to calibrate response, as the enhanced stability means the dose-effect relationship shifts. The evidence base for the amidate form is even more limited than for standard Selank, relying primarily on community pharmacokinetic reasoning rather than clinical data.

---

Build Your Personalised Protocol

Selank is one of many compounds available in the BioStack Generator. Explore cognitive and nootropic stacks alongside other compounds.

Get Your BioStack →